Nancy Pelosi Roasts a Luxury-Heavy Euro Portfolio Lacking US Tech

Good afternoon. Paul and I were just reviewing this portfolio over coffee, and I must say, it reads less like a modern investment strategy and more like the guest list at a G7 summit in Paris. It is incredibly elegant, deeply cultured, and impeccably dressed. You have built a lovely collection of European heritage brands and pharmaceutical giants. I have always admired the continent's commitment to luxury and lifestyle.

However, as I often remind my colleagues in the House: elegance does not necessarily equate to economic dominance. Investing is not about sentiment; it is about paying very close attention to the fundamentals and the macroeconomic realities that shape our world. You have assembled a portfolio that is entirely foreign, seemingly ignoring the greatest wealth-creation engine in the history of capitalism—the American economy. When I review a portfolio, I look for diligent research, strategic foresight, and alignment with structural tailwinds. This portfolio, while delightfully sophisticated, feels as though it missed a few crucial committee hearings on the future of global technology.

Let us review the composition of your holdings. Your geographic exposure is quite staggering—nearly 91% of this portfolio is allocated to Europe. While global diversification is a valid strategy, effectively boycotting North America is an astonishing decision.

Your sector breakdown shows a heavy reliance on Consumer Staples at over 21% and Consumer Discretionary at 16%. You have taken sizable, convicted positions in companies like LVMH, Nestle, and L'Oreal. I do appreciate the conviction here—sizing ASML at 12.4% and Novo Nordisk at 15.6% shows you understand that one must commit meaningful capital to dominant players. ASML, in particular, is a magnificent company; they provide the essential infrastructure for the semiconductor industry, a sector Paul and I follow very closely through proprietary research.

Furthermore, I note your portfolio relies heavily on the competitive moat of intangible assets and brands—nearly 66% of your allocation. People will always buy Birkin bags from Hermes and diabetes treatments from Novo Nordisk. But I must address your cash reserves, sitting at a mere 4.7%. In my experience, cash is strategic dry powder. When the right opportunity presents itself—and it always does—you need to be ready to act decisively. A 4% reserve leaves you with little to no flexibility to maneuver when the market inevitably presents a mispricing.

While this portfolio is undeniably profitable, it has several blind spots that we simply must address on the floor.

🚩 No American Technology Anchor

You have absolutely no US tech exposure. None. American technology companies, particularly in cloud computing, cybersecurity, and artificial intelligence, are the foundation of modern economic leadership. A portfolio without meaningful exposure to the US tech sector at this point has simply not been paying attention to the fundamentals. You are leaving historic, compounding returns on the table.

🚩 Ignoring Public Policy Tailwinds

Your allocation misses the massive legislative catalysts currently driving global markets. We have seen historic investments in domestic infrastructure, clean energy, and US semiconductor manufacturing. An investor who ignores the policy environment is flying blind. Relying on European spirits and cosmetics while the largest capital expenditure cycle in tech history is happening stateside is a profound misallocation of focus.

🚩 Insufficient Strategic Reserves

Holding less than 5% in cash signals a lack of preparedness. You are fully invested in a legacy market, leaving no room to average down or pivot when new research dictates a shift in strategy. Sitting idle with no dry powder is a failure of due diligence.

🚩 Yield Without Sufficient Growth

You have dedicated a significant portion of your capital to legacy European financials and industrials like Allianz, Zurich, and Siemens, alongside a token international bond ETF. While these provide steady income, yield without aggressive growth is a slow surrender to inflation. Safety that erodes purchasing power is not safety at all.

I give this portfolio a 5 out of 10. It is polite, it is composed, and it holds some undeniably excellent companies with strong monopolies. But it lacks the ambition and aggressive forward-looking research required to truly outpace the market over the next decade. This portfolio failed to pass committee on innovation.

Here are my actionable recommendations to amend this resolution:

1. Repatriate Your Capital: You must establish a strong American anchor. Begin rotating out of your slower-growing European staples (like Diageo) and initiate meaningful positions in US mega-cap technology and semiconductors.

2. Build Your Dry Powder: Trim some of your top-heavy positions to raise your cash reserves to at least 10-15%. You need liquidity to capitalize on market dislocations.

3. Align with Policy: Read the legislative room. Investigate American companies benefiting from infrastructure spending, cybersecurity mandates, and the reshoring of supply chains.

4. Rebalance the Moats: Brands and patents are lovely, but you need exposure to companies with high switching costs and network effects—specifically US enterprise software and cloud infrastructure.

In my experience, uncertainty is not a reason to do nothing — it is a reason to do the right thing. And usually, if you've done your homework, the right thing involves betting on American innovation.